Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the effectiveness of flutamide in reducing symptoms of premenstrual dysphoric disorder.


Clinical Trial Description

Premenstrual dysphoric disorder (PMDD) is a condition that affects about 5% of menstruating women. Women with PMDD experience serious emotional and physical disturbances, which may include depression, tension, irritability, anger, anxiety, and sleep and appetite problems. Symptoms of PMDD are directly linked with the menstrual cycle, generally beginning in the latter half of the cycle and ending around the start of the next cycle. If left unmanaged, PMDD may interfere with a woman's ability to carry out normal day-to-day functioning. Current treatments for PMDD include medications, psychotherapy, and nutritional modifications. Flutamide, a medication that blocks the action of testosterone and other mood-influencing hormones, may be helpful in alleviating symptoms of PMDD. This study will evaluate the effectiveness of flutamide in reducing symptoms of premenstrual dysphoric disorder.

This two-phase study will last a total of 4 months and will include 7 study visits. Phase 1 will last 2 months and will include Visits 1 through 3. During Phase 1, participants will keep a daily record of symptoms, participate in a diagnostic interview, and undergo a medical history review, a physical exam, and screening laboratory tests. Eligible participants will then enter Phase 2, the treatment phase of the study.

During the treatment phase, participants will be randomly assigned to take flutamide or placebo for 2 months. Study visits will occur every 2 weeks and will include Visits 4 through 7. These visits will include discussion of side effects, symptom rating, and laboratory tests to check for pregnancy and any side effects related to liver function, blood counts, or blood chemistry. At the end of treatment with flutamide or placebo, participants will have the option of receiving treatment with sertraline, an antidepressant known to be effective for many women with PMDD. Sertraline will be given during the 2 premenstrual weeks for two cycles. If participants have already unsuccessfully tried sertraline for PMDD treatment, an alternative treatment can be attempted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00611923
Study type Interventional
Source Weill Medical College of Cornell University
Contact
Status Completed
Phase Phase 4
Start date February 2005
Completion date December 2011

See also
  Status Clinical Trial Phase
Completed NCT02481973 - The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome Phase 2
Completed NCT00195559 - Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder Phase 3
Completed NCT00048854 - Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder Phase 1/Phase 2
Completed NCT00965562 - Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS) N/A
Completed NCT05349344 - Effect of Aerobic Exercise on Premenstrual Syndrome Symptoms (PMS). N/A
Recruiting NCT06146673 - A Multidimensional Study of Premenstrual Syndrome and Body Image
Recruiting NCT05836454 - The Soft Tissue Mobilization Techniques on PMS N/A
Completed NCT05499000 - The Effect of Emotional Freedom Technique on Premenstrual Syndrome N/A
Recruiting NCT06144073 - The Effect of Mandala Art Therapy in Coping With Premenstrual Syndrome N/A
Recruiting NCT06105567 - The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress N/A
Completed NCT03298607 - The Impact of Serelys PMS on Symptoms of PMS Phase 3
Recruiting NCT06176313 - Effects of Training Given to Cope With Premenstrual Syndrome and Mandala Activity on Premenstrual Symptoms N/A
Recruiting NCT02562053 - Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? Phase 3
Completed NCT00229346 - Fibromyalgia and Psychiatric Symptoms Among PMS and PMDD Patients N/A
Completed NCT00516113 - A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria Phase 4
Completed NCT04901598 - Physical Activity Level, Aerobic Capacity and Dietary Habits Among a Cohort of Females With Premenstrual Syndrome
Completed NCT05692479 - Premenstrual Syndrome and Physical Activity Self-Worth
Not yet recruiting NCT06052722 - The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders N/A
Completed NCT05665972 - Effects of Mandala Coloring on Premenstrual Syndrome N/A
Completed NCT05556252 - The Effect of Hydrogen-rich Water on Premenstrual Symptoms and Quality of Life N/A